On August 4, 2022, the company announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).
Ralph Lauren Q3 Adj. EPS $3.35 Beats $2.92 Estimate, Sales $1.83B Beat $1.76B Estimate
Ralph Lauren (NYSE:RL) reported quarterly earnings of $3.35 per share which beat the analyst consensus estimate of $2.92 by 14.73 percent. This is a 13.95 percent increase over earnings of $2.94 per share from the same
